Figure 3: Enhanced innate immunity against CT26 tumors after MBTA treatment.

A) Timing of tumor immunophenotyping (I.P.) experiments: I.P. experiments were completed on days 10 and 16 from the start of treatment to assess for immune cell populations at right and left flank tumors. Notably, I.P. Day 10 was completed 6 hours after in-situ injection of MBTA or saline (control) at the right flank tumors, whereas I.P. Day 16 was completed 6 days later to facilitate assessment of interim changes in immune cell populations; B & C) Percentage of CD45⁺ cells in total live tumor dissociated cells. I.P. Day 10 and I.P. 16 analyses demonstrate MBTA treated mice (pink) had significantly higher immune cells within both right and left flank tumors than saline-treated control mice (black). ** p < 0.01 by Mann-Whitney U test; D & E) Percentage of innate immune cells in total live tumor dissociated cells. Innate immune cells found within right and left flank tumors corresponding to I.P. Day 10 and 16 analyses are shown. Data is shown as individual data plots with median (line). *p < 0.05, ** p < 0.01 by Mann-Whitney U test. Example gating strategy for each cell population is demonstrated in Figure. S11 (Supporting Information). A total of 20 mice were used to complete immunophenotyping (I.P.) experiments. These were allocated to the following treatment groups: saline I.P. Day 10 (n=5); MBTA treatment I.P. Day 10 (n=5); saline I.P. Day 16 (n=5); MBTA treatment I.P. Day 16 (n=5).